|
1
|
Sloane BF, Herman CJ and Padarathsingh M:
Molecular mechanisms of progression and metastasis of human tumors:
a pathology B study section workshop. Working Report from the
Division of Research Grants. NIH Cancer Res. 54:5241–5245.
1994.PubMed/NCBI
|
|
2
|
Thomssen C, Schmitt M, Goretzki L, et al:
Prognostic value of the cysteine proteases cathepsins B and
cathepsin L in human breast cancer. Clin Cancer Res. 1:741–746.
1995.PubMed/NCBI
|
|
3
|
Kos J, Stabuc B, Schweiger A, et al:
Cathepsins B, H, and L and their inhibitors stefin A and cystatin C
in sera of melanoma patients. Clin Cancer Res. 3:1815–1822.
1997.PubMed/NCBI
|
|
4
|
Kayser K, Richter N, Hufnagl P, Kayser G,
Kos J and Werle B: Expression, proliferation activity and clinical
significance of cathepsin B and cathepsin L in operated lung
cancer. Anticancer Res. 23:2767–2772. 2003.PubMed/NCBI
|
|
5
|
Kos J and Lah TT: Cysteine proteinases and
their endogenous inhibitors: Target proteins for prognosis,
diagnosis and therapy in cancer (Review). Oncol Rep. 5:1349–1361.
1998.PubMed/NCBI
|
|
6
|
Kos J, Werle B, Lah T and Brunner N:
Cysteine proteinases and their inhibitors in extracellular fluids:
markers for diagnosis and prognosis in cancer. Int J Biol Markers.
15:84–89. 2000.PubMed/NCBI
|
|
7
|
Krepela E, Prochazka J, Karova B, Cermak J
and Roubkova H: Cysteine proteases and cysteine protease inhibitors
in non-small cell lung cancer. Neoplasma. 45:318–331.
1998.PubMed/NCBI
|
|
8
|
Andreasen PA, Kjoller L, Christensen L and
Duffy MJ: The urokinase-type plasminogen activator system in cancer
metastasis: a review. Int J Cancer. 72:1–22. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pedersen H, Grondahl-Hansen J, Francis D,
et al: Urokinase and plasminogen activator inhibitor type 1 in
pulmonary adenocarcinoma. Cancer Res. 54:120–123. 1994.PubMed/NCBI
|
|
10
|
Pedersen H, Brunner N, Francis D, et al:
Prognostic impact of urokinase, urokinase receptor, and type 1
plasminogen activator inhibitor in squamous and large cell lung
cancer tissue. Cancer Res. 54:4671–4675. 1994.PubMed/NCBI
|
|
11
|
Kos J, Smid A, Krasovec M, et al:
Lysosomal proteases cathepsins D, B, H, L and their inhibitors
stefins A and B in head and neck cancer. Biol Chem Hoppe Seyler.
376:401–405. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Schmitt M, Janicke F, Moniwa N,
Chucholowski N, Pache L and Graeff H: Tumor-associated
urokinase-type plasminogen activator: biological and clinical
significance. Biol Chem Hoppe Seyler. 373:611–622. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sukoh N, Abe S, Ogura S, et al:
Immunohistochemical study of cathepsin B. Prognostic significance
in human lung cancer. Cancer. 74:46–51. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kos J, Nielsen HJ, Krasovec M, et al:
Prognostic values of cathepsin B and carcinoembryonic antigen in
sera of patients with colorectal cancer. Clin Cancer Res.
4:1511–1516. 1998.PubMed/NCBI
|
|
15
|
Fujise N, Nanashim A, Taniguchi Y, et al:
Prognostic impact of cathepsin B and matrix metalloproteinase-9 in
pulmonary adenocarcinomas by immunohistochemical study. Lung
Cancer. 27:19–26. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Werle B, Kraft C, Lah TT, et al: Cathepsin
B in infiltrated lymph nodes is of prognostic significance for
patients with nonsmall cell lung carcinoma. Cancer. 89:2282–2291.
2000. View Article : Google Scholar
|
|
17
|
Cordes C, Bartling B, Simm A, et al:
Simultaneous expression of Cathepsins B and K in pulmonary
adenocarcinomas and squamous cell carcinomas predicts poor
recurrence-free and overall survival. Lung Cancer. 64:79–85. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cox JL, Sexton PS, Green TJ and Darmani
NA: Inhibition of B16 melanoma metastasis by overexpression of the
cysteine proteinase inhibitor cystatin C. Melanoma Res. 9:369–374.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kos J, Krasovec M, Cimerman N, Nielsen HJ,
Christensen IJ and Brunner N: Cysteine proteinase inhibitors stefin
A, stefin B, and cystatin C in sera from patients with colorectal
cancer: relation to prognosis. Clin Cancer Res. 6:505–511.
2000.PubMed/NCBI
|
|
20
|
Robert C, Bolon I, Gazzeri S, Veyrenc S,
Brambilla C and Brambilla E: Expression of plasminogen activator
inhibitors 1 and 2 in lung cancer and their role in tumor
progression. Clin Cancer Res. 5:2094–2102. 1999.PubMed/NCBI
|
|
21
|
Salden M, Splinter TA, Peters HA, et al:
The urokinase-type plasminogen activator system in resected
non-small-cell lung cancer. Rotterdam Oncology Thoracic Study
Group. Ann Oncol. 11:327–332. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Almasi CE, Hoyer-Hansen G, Christensen IJ
and Pappot H: Prognostic significance of urokinase plasminogen
activator receptor and its cleaved forms in blood from patients
with non-small cell lung cancer. Acta Pathol Microbiol Immunol
Scand Suppl. 117:755–761. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Corticchiato O, Cajot JF, Abrahamson M,
Chan SJ, Keppler D and Sordat B: Cystatin C and cathepsin B in
human colon carcinoma: expression by cell lines and matrix
degradation. Int J Cancer. 52:645–652. 1992. View Article : Google Scholar : PubMed/NCBI
|
